Remodelling of high density lipoproteins by plasma factors

Atherosclerosis

Volumn 145, Issue 2, 1999, Pages 227-238

  Rye, Kerry Anne ^a   Clay, Moira A ^b   Barter, Philip J ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apolipoprotein A I; Apolipoprotein A II; High density lipoproteins; Plasma factors; Remodelling

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2;

ATHEROGENESIS; ENDOTHELIUM CELL; HUMAN; HYDROLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; PARTICLE SIZE; PLASMA FACTOR; PRIORITY JOURNAL; REVIEW;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; GLYCOPROTEINS; HUMANS; LIPASE; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASES A; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS; STEROL O-ACYLTRANSFERASE;

EID: 0032812981     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00150-1     Document Type: Review

References (140)

1. Hamilton RL, Williams MC, Fielding CJ, Havel RJ. Discoidal bilayer structures of nascent high density lipoproteins from perfused rat liver. J Clin Invest 1976;58:667-80.
2. Clay MA, Barter PJ. Formation of new HDL particles from lipid-free apolipoprotein A-I. J Lipid Res 1996;37:1722-32.
3. Forte TM, Bielecki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res 1995;36:148-57.
4. Redgrave TG, Small DM. Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during the catabolism of chylomicrons in the rat. J Clin Invest 1979;64:162-71.
5. Tall AR, Blum CB, Forester GP, Nelson CA. Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat. J Biol Chem 1982;257:198-8.
6. Fidge NH, Nestel P, Ishikawa T, Reardon MF, Billington T. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic subjects. Metabolism 1980;29:643-53.
7. Schaefer EJ, Zech LA, Jenkins LL, et al. Human apolipoprotein A-I and A-II metabolism. J Lipid Res 1982;23:850-62.
8. Jordan-Starck TC, Witte DP, Aronow BJ, Harmony JAK. Apolipoprotein J: a membrane policeman? Curr Opin Lipidol 1992;3:75-85.
9. McConathy WJ, Alaupovic P. Isolation and characterization of other apolipoproteins. Meth Enzymol 1986;128:297-310.
10. Mahley RW, Innerarity TL, Tall SCJ, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984;25:1277-94.
11. Cheung MC, Wolf AC, Lum KD, Tollefson JH, Albers JJ. Distribution and localization of lecithin:cholesterol acyl transferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J Lipid Res 1986;27:1135-44.
12. Francone OL, Gurakar A, Fielding CJ. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. J Biol Chem 1989;264:7066-72.
13. Marcel YL, McPherson R, Hogue M, et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest 1990;85:10-7.
14. Pattnaik NM, Zilversmit DB. Interaction of cholesteryl ester exchange protein with human plasma lipoproteins and phospholipid vesicles. J Biol Chem 1979;254:2782-6.
15. Tall AR, Abreu E, Shuman J. Separation of a plasma phospholipid transfer protein from cholesteryl ester/phospholipid exchange protein. J Biol Chem 1983;258:2174-80.
16. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible role for paraoxonase. J Clin Invest 1998;101:1581-90.
17. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
18. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997;349:851-2.
19. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JAK. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994;33:832-9.
20. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871-9.
21. Bagdade JD, Buchanan WF, Pollare T, Lithell H. Abnormal lipoprotein phospholipid composition in patients with essential hypertension. Atherosclerosis 1995;117:209-15.
22. Davidson WS, Sparks DL, Lund-Katz S, Phillips MC. The molecular basis for the difference in charge between pre-β- and α-migrating high density lipoproteins. J Biol Chem 1994;269:8959-65.
23. Subbaiah PV, Monshizadegan H. Substrate specificity of human plasma lecithin:cholesterol acyltransferase towards molecular species of phosphatidylcholine in native plasma. Biochim Biophys Acta 1988;963:445-55.
24. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apolipoprotein composition: particles with A-I and A-II and particles with A-I but not A-II. J Lipid Res 1982;23:747-53.
25. Bekaert ED, Alaupovic P, Knight-Gibson C, et al. Isolation and partial characterization of lipoprotein A-II (LP A-II) particles of human plasma. Biochim Biophys Acta 1992;1126:105-13.
26. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
27. Czarnecka H, Yokoyama S. Regulation of lecithin-cholesterol acyltransferase reaction by acyl acceptors and demonstration of its 'idling' reaction. J Biol Chem 1993;268:19334-40.
28. Subbaiah PV, Chen C-H, Bagdade JD, Albers JJ. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J Biol Chem 1985;260:5308-14.
29. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta 1991;1084:205-20.
30. Barter PJ, Hopkins GJ, Gorjatschko L. Lipoprotein substrates for plasma cholesterol esterification: influence of particle size and the high density lipoprotein subfraction-3. Atherosclerosis 1985;58:97-107.
31. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.
32. Wiebusch H, Cullen P, Owen JS, et al. Deficiency of lecithin:cholesterol acyltransferase due to compound heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the LCAT gene. Hum Mol Genet 1995;4:143-5.
33. von Eckardstein A, Huang Y, Wu S, Funke H, Noseda G, Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol 1995;15:691-703.
34. Sakai N, Vaisman BL, Koch CA, et al. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem 1997;272:7506-10.
35. Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM. Disruption of the murine lecithin:cholesterol acyl-transferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem 1997;272:15777-81.
36. Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem J 1982;208:1-7.
37. Hesler CB, Swenson T, Tall AR. Purification and characterization of human plasma cholesteryl ester transfer protein. J Biol Chem 1987;262:2275-82.
38. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77.
39. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998;141:87-98.
40. McPherson R, Mann CJ, Tall AR, et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinaemia. Relation to cholesteryl ester transfer activity and other lipoprotein variables. Arterioscler Thromb 1991;11:797-804.
41. Riemens S, van Tol A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9.
42. Tall A. Plasma lipid transfer proteins. Ann Rev Biochem 1995;64:235-57.
43. Tollefson JH, Ravnik S, Albers JJ. Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J Lipid Res 1988;29:1593-602.
44. Nishida HI, Nishida T. Phospholipid transfer protein mediates transfer of not only phosphatidylcholine but also cholesterol from phosphatidylcholine-cholesterol vesicles to high density lipoproteins. J Biol Chem 1997;272:6959-64.
45. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm CP. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993;268:4032-6.
46. Vieira-van Bruggen D, Kalkman I, van Gent T, van Tol A, Jansen H. Induction of adrenal scavenger receptor BI and increased high density lipoprotein-cholesteryl ether uptake by in vivo inhibition of hepatic lipase. J Biol Chem 1998;273:32038-41.
47. Wang N, Weng W, Breslow JL, Tall AR. Scavenger Receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knockout mice as a response to depletion of cholesterol stores. J Biol Chem 1996;271:21001-4.
48. Dichek HL, Brecht W, Fan J, et al. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins: evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J Biol Chem 1998;273:1896-903.
49. Choi SY, Goldberg IJ, Curtiss LK, Cooper AD. Interaction between apoB and hepatic lipase mediates the uptake of apoB-containing lipoproteins. J Biol Chem 1998;273:20456-62.
50. Ehnholm CP, Shaw W, Greten H, Brown WV. Purification from human plasma of a heparin-releasable lipase with activity against triglyceride and phospholipid. J Biol Chem 1975;250:6756-61.
51. Groot PHE, Scheek LM, Jansen H. Liver lipase and high-density lipoprotein. Lipoprotein changes after incubation of human serum with rat liver lipase. Biochim Biophys Acta 1983;751:393-400.
52. Kuusi T, Kinnunen PKJ, Nikkila EA. Hepatic endothelial lipase antiserum influences rat plasma low and high density lipoproteins in vivo. FEBS Lett 1979;104:384-8.
53. Musliner TA, Herbert PN, Kingston MJ. Lipoprotein substrates of lipoprotein lipase and hepatic triacylglycerol lipase from human postheparin plasma. Biochim Biophys Acta 1979;575:277-88.
54. 2-phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun 1981;100:591-9.
55. Deckelbaum RJ, Ramakrishnan R, Eisenberg S, Olivecrona T, Bengtsson-Olivecrona G. Triacylglycerol and phospholipid hydrolysis in human plasma lipoproteins: role of lipoprotein and hepatic lipase. Biochemistry 1992;31:8544-51.
56. Hime NJ, Barter PJ, Rye K-A. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem 1998;273:27191-8.
57. Clay MA, Newnham HH, Barter PJ. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler Thromb 1991;11:415-22.
58. Hopkins GJ, Barter PJ. Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 1986;27:1265-77.
59. Perret BP, Collet F, Durand S, Simard G, Chap H, Douste-Blazy L. Distribution of high-density lipoprotein 2 and 3 constituents during in vitro phospholipid hydrolysis. Eur J Biochem 1987;162:279-86.
60. Marques-Vidal P, Jauhiainen M, Metso J, Ehnholm CP. Transformation of high density lipoprotein 2 particles by hepatic lipase and phospholipid transfer protein. Atherosclerosis 1997;133:87-95.
61. Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998;35:547-72.
62. Knudsen P, Antikainen M, Ehnholm S, et al. A compound heterozygote for hepatic lipase gene mutations Leu334→Phe and Thr383→Met: correlation between hepatic lipase activity and phenotypic expression. J Lipid Res 1996;37:825-34.
63. Knudsen P, Antikainen M, Uusi-Oukari M, et al. Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene. Atherosclerosis 1997;128:165-74.
64. Clay MA, Hopkins GJ, Ehnholm CP, Barter PJ. The rabbit as an animal model of hepatic lipase deficiency. Biochim Biophys Acta 1989;1002:173-81.
65. Applebaum-Bowden D, Kobayashi J, Kashyap VS, et al. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus mediated replacement of a lipolytic enzyme in the vascular endothelium. J Clin Invest 1996;97:799-805.
66. Homanics GE, de Silva H, Osada J, et al. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J Biol Chem 1995;270:2974-80.
67. 2 and prostacyclin production by proliferating rat smooth muscle cells. Prostaglandins 1993;46:331-46.
68. 2 by rat mesangial cells. J Clin Invest 1993;92:2516-23.
69. 2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991;266:2647-51.
70. 2 secreted and anchored on cell-surface heparan sulfate proteoglycan. Eur J Biochem 1993;218:807-13.
71. 2 gene expression in human bronchial epithelial cells. Biochim Biophys Acta 1996;1310:175-84.
72. 2: preferential hydrolysis of acute phase HDL. J Lipid Res 1998;39:2150-60.
73. Green PHR, Glickman RM. Intestinal lipoprotein metabolism. J Lipid Res 1981;22:1153-73.
74. Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoprotein with pre-beta electrophoretic mobility. J Lipid Res 1985;26:549-55.
75. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β migrating high-density lipoprotein. Biochemistry 1988;27:25-9.
76. Sviridov D, Fidge NH. Pathways of cholesterol efflux from human hepatoma cells. Biochim Biophys Acta 1995;1256:210-20.
77. Huang Y, von Eckardstein A, Assmann G. Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 1993;13:445-58.
78. Nichols AV, Gong EL, Blanche PJ, Forte TM, Shore VG. Molecular pathways in the transformation of model discoidal lipoprotein complexes induced by lecithin:cholesterol acyl transferase. Biochim Biophys Acta 1985;834:285-300.
79. Liang H-Q, Rye K-A, Barter PJ. Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim Biophys Acta 1995;1257:31-7.
80. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm CP. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 1996;313:275-82.
81. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981;665:408-19.
82. Forte TM, Nichols AV. Application of electron microscopy to the study of plasma lipoprotein structure. Adv Lipid Res 1972;10:1-41.
83. Cheung MC, Nichols AV, Blanche PJ, Gong EL, Franceschini G, Sirtori CR. Characterization of A-I-containing lipoproteins in subjects with A-I Milano variant. Biochim Biophys Acta 1988;960:73-82.
84. Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996;94:2177-84.
85. Mehlum A, Staels B, Duverger N, et al. Tissue-specific expression of the human gene for lecithin:cholesterol acyltransferase in trangenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur J Biochem 1995;230:567-75.
86. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein All on plasma lipoprotein cholesterol metabolism. J Clin Invest 1995;96:1440-8.
87. Vaisman BL, Klein H-G, Rouis M, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995;270:12269-75.
88. Berard AM, Foger B, Remaley A, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nature Med 1997;3:744-9.
89. Dugi KA, Vaisman BL, Sakai N, et al. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res 1997;38:1822-32.
90. Hoeg JM, Vaisman BL, Demosky SJ Jr, et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996;271:4396-402.
91. Hoeg JM, Santamarina-Fojo S, Berard AM, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 1996;93:11448-53.
92. Brousseau ME, Santamarina-Fojo S, Zech LA, et al. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest 1996;97:1844-51.
93. Liang H-Q, Rye K-A, Barter PJ. Remodelling of reconstituted high density lipoproteins by lecithin:cholesterol acyltransferase. J Lipid Res 1996;37:1962-70.
94. Albers JJ, Wolfbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995;1258:27-34.
95. Rye K-A, Jauhiainen M, Barter PJ, Ehnholm CP. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 1998;39:613-22.
96. Ehnholm S, van Dijk KW, van't Hof B, et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res 1998;39:1248-53.
97. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein. Adenovirus mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 1997;272:27393-400.
98. Jiang X-C, Francone OL, Bruce C, et al. Increased pre-β-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996;98:2373-80.
99. Pussinen PJ, Jauhiainen M, Metso J, Tyynela J, Ehnholm CP. Pig phospholipid transfer protein facilitates HDL interconversion. J Lipid Res 1995;36:975-85.
100. von Eckardstein A, Jauhiainen M, Huang Y, et al. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre-β1 HDL. Biochim Biophys Acta 1996;1301:255-62.
101. Barter PJ, Chang LBF, Newnham HH, Rye K-A, Rajaram OV. The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high density lipoproteins. Biochim Biophys Acta 1990;1045:81-9.
102. Deckelbaum RJ, Eisenberg S, Oschry Y, Granot E, Sharon I, Bengtsson-Olivecrona G. Conversion of human plasma high density lipoprotein-2 to high density lipoprotein-3. Roles of neutral lipid exchange and triglyceride lipases. J Biol Chem 1986;261:5201-8.
103. Clay MA, Newnham HH, Forte TM, Barter PJ. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apoA-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta 1992;1124:52-8.
104. Clay MA, Rye K-A, Barter PJ. Evidence that hepatic lipase reduces the concentration of apolipoprotein A-I in rabbit high-density lipoproteins. Biochim Biophys Acta 1990;1044:50-6.
105. 2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem 1994;269:11572-7.
106. Melchior GW, Castle CK, Murray RW, Blake WL, Dinh DM, Marotti KR. Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J Biol Chem 1994;269:8044-51.
107. Liu XQ, Bagdade JD. Neutral lipid mass transfer among lipoprotein in plasma from normolipidemic subjects is not an equimolar heteroexchange. J Lipid Res 1995;36:2574-9.
108. Rye K-A, Hime NJ, Barter PJ. The influence of cholesteryl ester transfer protein on the composition, size and structure of spherical, reconstituted high density lipoproteins. J Biol Chem 1995;270:189-96.
109. Liang H-Q, Rye K-A, Barter PJ. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J Lipid Res 1994;35:1187-99.
110. Agellon LB, Walsh A, Hayek A, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991;266:10796-801.
111. Atger V, de la Llera Moya M, Bamberger M, et al. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. J Clin Invest 1995;96:2613-22.
112. Francone OL, Royer L, Haghpassand M. Increased pre-β-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expression the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 1996;37:1268-77.
113. Hayek T, Chajek-Saul T, Walsh A, et al. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest 1992;90:505-10.
114. Dinchuk J, Hart J, Gonzalez G, Karmann G, Schmidt D, Wirak DO. Remodelling of lipoproteins in transgenic mice expressing human cholesteryl ester transfer protein. Biochim Biophys Acta 1995;1255:301-10.
115. Marotti KR, Castle CK, Murray RW, Rehberg EF, Polites HG, Melchior GW. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb 1992;12:736-44.
116. Hayek T, Azrolan N, Verdery RB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle size, and metabolism. Studies in transgenic mice. J Clin Invest 1993;92:1143-52.
117. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow JL, Tall A. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J Clin Invest 1994;94:2457-67.
118. Oliveira HCF, Ma L, Milne R, et al. Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997;17:1045-52.
119. Rye K-A, Hime NJ, Barter PJ. Evidence that CETP-mediated reductions in reconstituted high density lipoprotein size involves particle fusion. J Biol Chem 1997;272:3953-9.
120. van Tol A, van Gent T, Jansen H. Degradation of high density lipoprotein by heparin-releasable liver lipase. Biochem Biophys Res Commun 1980;94:101-8.
121. Busch SA, Barnhart RL, Martin GA, et al. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994;269:16376-82.
122. Fan J, Wang J, Bensadoun A, et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA 1994;91:8724-8.
123. Horowitz BS, Goldberg IJ, Merab J, Vannit T, Ramakrishnan R, Ginsberg HN. Role of the kidney in increased clearance of apolipoprotein A-I in subjects with reduced high density lipoprotein cholesterol concentrations. In: Miller NE, Tall AR, editors. High Density Lipoproteins and Atherosclerosis III. Amsterdam: Excerpta Medica, 1992:215-22.
124. Bielecki JK, Johnson WJ, Weinberg RB, Glick JM, Rothblat GH. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res 1992;33:1699-709.
125. Hara H, Yokoyama S. Role of apolipoproteins in cholesterol efflux from macrophages to lipid emulsions: proposal of a putative model for the pre-β high-density lipoprotein pathway. Biochemistry 1992;31:2040-6.
126. Tam SP, Breckenridge WC. Apolipoprotein and lipid distribution between vesicles and HDL-like particles formed during lipolysis of human very low density lipoproteins by perfused rat heart. J Lipid Res 1983;24:1343-57.
127. Vigne J-L, Havel RJ. Metabolism of apolipoprotein A-I of chylomicrons in rats and humans. Can J Biochem 1981;59:613-8.
128. Glass C, Pittman RC, Civen M, Steinberg D. Uptake of high-density lipoprotein-associated apoprotein A-I and cholesteryl esters by 16 tissues of the rat in vivo and by adrenal glands and hepatocytes in vitro. J Biol Chem 1985;260:744-50.
129. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol from that of apoprotein A-I of rat high density lipoproteins: selective delivery of cholesterol to liver, adrenal and gonad. Proc Natl Acad Sci USA 1985;80:5435-9.
130. Acton S, Rigotti A, Landschulz K, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-20.
131. Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996;98:984-95.
132. Eggerman TL, Hoeg JM, Meng MS, Tombragel A, Bojanovski D, Brewer HB Jr. Differential tissue-specific expression of human apoA-I and apoA-II. J Lipid Res 1991;32:821-8.
133. Jonas A, Sweeny SA, Herbert PN. Discoidal complexes of A and C apolipoproteins with lipids and their reactions with lecithin:cholesterol acyltransferase. J Biol Chem 1984;259:6369-75.
134. Clay MA, Cehic DA, Pyle DH, Rye K-A, Barter PJ. Formation of apolipoprotein-specific high density lipoproteins from lipid-free apolipoproteins A-I and A-II. Biochem J 1998;337:445-51.
135. Rosseneu M, Van Tornout P, Lievens M-J, Assmann G. Displacement of the human apoprotein A-I by the human apoprotein A-II from complexes of (apoprotein A-I)-phosphatidylcholine-cholesterol. Eur J Biochem 1981;117:347-52.
136. Edelstein C, Halari M, Scanu AM. On the mechanism of the displacement of apolipoprotein A-I by apolipoprotein A-II from the high density lipoprotein surface. J Biol Chem 1982;257:7189-95.
137. Rye K-A, Barter PJ. The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. J Biol Chem 1994;269:10298-303.
138. Durbin DM, Jonas A. The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem 1997;272:31333-9.
139. Pussinen PJ, Jauhiainen M, Ehnholm CP. ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J Lipid Res 1997;38:12-21.
140. Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997;38:1289-98.